Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus CORTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus CORTAN.
CAPEX vs CORTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid